HighTower Advisors LLC Invests $38,000 in Fractyl Health, Inc. (NASDAQ:GUTS)

HighTower Advisors LLC bought a new stake in shares of Fractyl Health, Inc. (NASDAQ:GUTS) in the 3rd quarter, Holdings Channel reports. The firm bought 15,000 shares of the company’s stock, valued at approximately $38,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers bought a new stake in shares of Fractyl Health in the 2nd quarter worth $32,000. SG Americas Securities LLC bought a new stake in shares of Fractyl Health during the 3rd quarter valued at about $33,000. Beta Wealth Group Inc. bought a new position in Fractyl Health in the third quarter worth approximately $44,000. BNP Paribas Financial Markets lifted its position in Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Fractyl Health in the 2nd quarter worth approximately $61,000.

Insiders Place Their Bets

In other Fractyl Health news, CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $1,213,582.63. The trade was a 16.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at $379,253.68. This represents a 29.48 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $2.06 on Friday. Fractyl Health, Inc. has a 1-year low of $1.74 and a 1-year high of $14.50. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The company has a market capitalization of $99.08 million and a P/E ratio of -0.17. The firm’s 50 day simple moving average is $2.34 and its two-hundred day simple moving average is $3.08.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. Research analysts expect that Fractyl Health, Inc. will post -1.66 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.